Libsyn Directory

#381 A New Era for EU and UK Deals? The EC’s Draft Merger Guidelines and the CMA’s Growth Approach

Release Date: 06/08/2026

#400 Is California Dreamin’ of Merger Challenges? Diving Into the Golden State’s HSR Notification Regime

Our Curious Amalgam

State-level pre-merger notification requirements are becoming more popular. But what is happening in California? Heather Greenfield, partner at White & Case, joins Jaclyn Phillips and Puja Patel to discuss how California's law fits into an overall notification strategy. Listen to this episode to learn more about what to expect and how to prepare when the law becomes effective on January 1, 2027. With special guest: Heather Greenfield, Partner, White & Case Hosted by: Jaclyn Phillips, Proskauer Rose and Puja Patel, Cleary Gottlieb Steen & Hamilton

#399 Who Has the Inside Track on Litigation Risk? An In-House View From the Markets

Our Curious Amalgam

What does competition and litigation risk look like from inside a company operating at the intersection of financial markets, data, technology, and regulation? Kay Lynn Brumbaugh, Head of Litigation, Group Legal at London Stock Exchange Group plc (LSEG), joins Anora Wang and Matthew Hall to share an in-house perspective on managing disputes in a highly regulated global business. Listen to this episode to learn how issues involving data access, market infrastructure, AI, and overlapping regulatory regimes look from inside the client. With special guest: Kay Lynn Brumbaugh, Head of Litigation,...

#398 What's 340B? An Economist's View of the Recent Wave of 340B Litigation

Our Curious Amalgam

The Federal 340B Drug Pricing Program has grown from a modest drug discount program into a massive federal program involving pharmaceutical manufacturers, hospitals, pharmacies, insurers, and third-party administrators. But when can similar conduct by participants in this program suggest coordination or raise other competition concerns? Archan Ruparel, economist at Charles River Associates, joins Brian Auricchio and Jaclyn Phillips to discuss economic considerations when evaluating potential antitrust concerns relating to 340B. Listen to this episode to learn more about factors that can help...

#397 What’s Next for the ABA Antitrust Law Section? Stability, Balance, and Value

Our Curious Amalgam

What’s ahead for the ABA Antitrust Law Section in 2026–2027? Section Chair Melanie Aitken and Counsel to the Chair Christina Skinner join Our Curious Amalgam to discuss Melanie’s vision for the Section and her priorities for the coming year. Listen to this episode to learn how under Melanie’s leadership, the Section plans to double down on its value to members, strengthen its leadership and processes, and remain a home for vigorous debate and a broad range of perspectives across the antitrust community. With special guests: Melanie Aitken, Chair, ABA Antitrust Law Section and...

#396 Is EU Law on Abuse of Dominance Now Clear? The ECJ’s Judgment in Google Android

Our Curious Amalgam

The European Court of Justice's judgment in Google Android is one of the most consequential EU competition law judgments of the last decade. But why is it so important? Thomas Höppner, lawyer at Geradin Partners, joins Matthew Hall and Subrata Bhattacharjee to discuss the key issues raised and their relevance to abuse of dominance cases generally. Listen to this episode to learn more about counterfactual analysis, the relevance of context and the latest on the as-efficient-competitor test and principle. With special guest: Thomas Höppner, partner, Geradin Partners Related Links: Hosted by:...

#395 Which Side of the V? Larry Buterman on Trying Antitrust Cases for the Government and Against It

Our Curious Amalgam

Larry Buterman is one of the rare antitrust attorneys who has successfully first chaired landmark cases both at the DOJ Antitrust Division and in private practice. In this career profile, co-hosts Derek Jackson and Lexi Michaud ask Larry about the differences and similarities in representing the DOJ versus representing a private party, about Larry's trial war stories (including his cross-examination of a famous athlete), about advice for aspiring litigators, and more. Listen to this episode to learn about the experience of an antitrust trial lawyer and how you might become one too. With...

#394 A Tribute to Randy Picker: Revisiting Episode #74 on the Implications of DOJ's Case Against IBM

Our Curious Amalgam

We are re-releasing this episode in tribute to Prof. Randy Picker, who passed away on August 15, 2026. In 2020, Randy joined co-hosts Anora Wang and John Roberti for an episode on the 13-year-long U.S. antitrust case against IBM brought in 1969, exploring how U.S. antitrust dealing with tech ranges from early government cases involving punch cards to government probes into today's platforms, and how antitrust enforcement can impact the technology landscape for decades later. Years later, the episode holds up remarkably well - the questions Randy raised about whether the antitrust past would...

#393 Who Gets To Say the Price Is Right? State Regulation of AI Pricing

Our Curious Amalgam

Several U.S. states have recently passed legislation aimed at AI pricing tools that use consumer or competitor data. What is driving this spate of legislation, what different approaches are the states taking, and are the states sufficiently accounting for possible unintended consequences? In this episode, hosts Sergei Zaslavsky and Alicia Downey talk to Orrick partner Shannon Yavorksy about the pros and cons of AI pricing and the emerging regulatory patchwork in this area. Listen to this episode to hear about the latest developments in AI pricing regulation and what the future might hold. With...

#392 Do I Really Need To File? HSR Avoidance and the Edwards/Genesis Settlement

Our Curious Amalgam

For nearly 50 years, the Hart-Scott-Rodino Act has given antitrust enforcers a chance to review deals above a certain value before they can close. What happens when the government concludes a transaction was structured intentionally to slip past that review entirely? On this episode of Our Curious Amalgam, we speak with Evan Miller of Vinson & Elkins about HSR Act avoidance and the FTC’s record-setting $12 million settlement with Edwards Lifesciences and Genesis MedTech over Edwards Lifesciences’s acquisition of JC Medical from Genesis. We discuss how the JC Medical deal was valued and...

#391 Have States Found the Answer to Subscription Traps? Click-to-Cancel and Beyond

Our Curious Amalgam

State legislatures across the country are taking aim at subscription traps and deceptive cancellation practices — but what does effective consumer protection actually look like at the state level? Erin Witte, Senior Counsel to the New Jersey Attorney General and former Director of Consumer Protection at the Consumer Federation of America, speaks with Anna Olson and Anora Wang about the growing wave of state click-to-cancel legislation targeting subscription traps and dark patterns. Listen to this episode to learn what makes a strong state law, how enforcement actions actually unfold, and...

More Episodes

The analysis of mergers in the EU and UK is adapting to take account of a changed worldwide geo-political and trade context. But what does this mean in practice? Stuart Hudson, co-lead of Brunswick’s global regulatory practice, joins Matthew Hall and James Hunsberger to discuss the European Commission's draft new EU Merger Guidelines and changes in the UK. Listen to this episode to learn more about what is in the draft EU guidelines, why the changes have been made, the UK's new approach, a prediction on EU/UK convergence or divergence and the risk of politicisation of merger control.

With special guest:
Stuart Hudson, co-lead global regulatory practice, Brunswick Group

Related Links:

Hosted by:
Matthew Hall, McGuireWoods and James Hunsberger, Axinn, Veltrop & Harkrider

TOPICS